OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopath

OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopathy. Note Omeros markets Yartemlea (narsoplimab), which is approved for hematopoietic stem cell transplant–associated thrombotic microangiopathy.